Effective ocular gene delivery requires platforms capable of efficiently delivering genetic material to retinal cells while supporting therapeutic development for diseases of the eye. Cytofinity™-OP demonstrates efficient intracellular delivery of genetic material to human ARPE-19 retinal cells in vitro and high-efficiency delivery to the eye in preclinical mouse studies following intravitreal administration.
In addition, Cytofinity™-OP exhibits an intrinsic anti-inflammatory effect through its “Self-Molecule” mechanism, highlighting its potential as a platform for next-generation ocular genetic therapies.
Target Tissues:
- Eye (intravitreal)
Potential Applications:
- Glaucoma
- Age-related Macular Degeneration (AMD)
- Inherited Retinal Disease (IRDs)